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.2013.05Abstract Background: Increased prevalence of antinuclear antibodies (ANA) and auto glutamic
acid decarboxylase antibodies (GADA) ratio have been reported in patients with epilepsy. Anti-
GAD antibodies (GADA) were ﬁrst implicated in the pathogenesis of some neurological diseases
including epilepsy.
The aim of the study: To determine the occurrence of GADA and ANA in the serum of children
with refractory epilepsy.
Patients and methods: Forty children with refractory epilepsy 25 males and 15 females, mean age
9.17 ± 3.4 years were selected for this study. Patients with refractory epilepsy had recurrent seizures
for more than 18 months with no more than a 3-month seizure free period during those 18 months
and failure of at least two appropriate AEDs with proper doses, good compliance and within nor-
mal therapeutic range. Twenty children with controlled idiopathic epilepsy 15 males and 5 females
newly diagnosed as suffering from various types of seizures generalized and partial types, mean age
10.1 ± 3.1 years were also included in this study. These children with idiopathic epilepsy were
included in this study for comparison with children with refractory epilepsy as regard to the serum
ANA and GADA.
Results: Children with refractory epilepsy had high-serum levels of GADA and ANA in compar-
ison to children with idiopathic epilepsy (P< 0.001), also there was a signiﬁcant correlation
between the duration of seizures and the serum levels of ANA and GADA in children with refrac-
tory epilepsy.002415438.
.com (H. El-Serogy).
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Antinuclear antibodies and glutamic acid decarboxylase antibodies in children with refractory 47Conclusion: Children with refractory epilepsy had high-titer of GADA and ANA. The ﬁnding con-
ﬁrmed the association between high GADA, ANA and refractory epilepsy suggesting an immuno-
logic origin of refractory epilepsy.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric Association.Table 1 Characteristics of children with refractory epilepsy.
Age in years
Range 4–15
Mean 9.17 ± 3.4
Patient number 40
Sex (males/females) 25/15
Currently used AEDs
Two AEDs 32 (80%)
Three AEDs 8 (20%)
Duration of treatment in months
Range 24–60
Mean ± SD 43 ± 11.4
Age of the ﬁrst seizure in years
Range 3–9
Mean 6.72 ± 1.8
(EEG) ﬁnding
Generalized epileptogenic activity 20 (50%)
Focal epileptogenic activity 12 (30%)
Multifocal generalized epileptogenic activity 6 (15%)
No abnormalities 2 (5%)Introduction
Epilepsy represents the most common serious neurological
problem-affecting children, with an overall incidence
approaching 2% for febrile seizures and 1% for idiopathic epi-
lepsy.1,2 At present, the epilepsy of childhood is most fre-
quently classiﬁed using variations of the International
Classiﬁcation of Epileptic Seizures.3 This nomenclature delin-
eates seizures in three general categories: generalized, partial
(focal), and special epileptic syndromes.4 Epilepsy is a benign
condition in the majority of cases, and 60–70% of patients
who are diagnosed with epilepsy will eventually enter remis-
sion when adequately treated with antiepileptic drugs
(AEDs).5 In 40–60% of these seizure free individuals, AEDs
can be successfully withdrawn after a reasonable period of
time.6 About one third of patients with newly diagnosed epi-
lepsy do not achieve seizure control despite medical therapy
and should be assessed in detail to conﬁrm the diagnosis, to
determine the epilepsy syndrome and to plan treatment strat-
egy.7 Refractory epilepsy is established when there is inade-
quate seizure control despite using potentially effective
antiepileptic drugs (AEDs) at tolerable levels for 2 years, and
excluding non epileptic events and poor compliance.8 Some
authors deﬁne intractable epilepsy as failure of two appropri-
ate AEDs, the occurrence of an average of one seizure per
month for P18 months, and no more than a 3-month seizure
free period during those 18 months.9 Risk factors for refracto-
riness include (1) generalized epilepsy with lesions; (2) focal
epilepsy with hippocampus sclerosis, cortical dysplasia or hem-
orrhages; (3) early epilepsy onset; (4) high seizure frequency;
(5) absence of response to the ﬁrst 2 AEDs; (6) high frequency
of inter ictal spikes; (7) multifocal spikes. A younger age at on-
set of epilepsy predicts refractoriness.10 The concept that the
immune system plays a role in the epileptogenic process of
some epileptic syndromes was ﬁrst proposed more than
20 years ago.11 Since then numerous studies have reported
on the existence of a variety of immunological alterations in
epileptic patients, on the observation of favorable responses
of refractory epilepsy syndromes to immunomodulatory treat-
ment.12 Over the last few years, antibodies to intracellular pro-
teins such as glutamic acid decarboxylase (GAD) and
antinuclear antibodies (ANA) have been detected in the serum
and cerebrospinal ﬂuid of patients with certain forms of epi-
lepsy.13 The increased prevalence of autoantibodies is more
strongly associated with epilepsy, perhaps indicating that im-
mune dysregulation may be commonly associated with epi-
lepsy.14 Previous studies have shown the association between
antinuclear antibodies and epilepsy but there are no studies
addressing the effect of seizure frequency, duration of epilepsy,
epilepsy type and etiology on the prevalence of these antibod-
ies in well-evaluated refractory epilepsy.15 Glutamic acid
decarboxylase (GAD) catalyzes the transformation of gluta-
mate into c-hydroxybutyric acid (GABA), both are major neu-
rotransmitters of the central nervous system.16 GAD primarilyis expressed in GABA-secreting neurons and in pancreatic b
cells, which also may secrete GABA as a paracrine signal mol-
ecule.17 Glutamic acid decarboxylase antibodies (GADA) have
been detected in patients with epilepsy; some patients with
drug-resistant localization-related epilepsy have evidence of
GAD autoimmunity.18 The presence of autoantibodies to
brain endothelial cells suggests that autoimmunity may be
important in the pathogenesis of epilepsy.19
The aim of the study
We studied the frequency of antinuclear antibodies (ANA) and
autoantibodies to glutamic acid decarboxylase (GADA) in the
serum of children with refractory epilepsy and compared them
with children with controlled idiopathic epilepsy to delineate if
immune mechanisms might be participating in the mechanism
of refractory epilepsy and to determine whether autoantibodies
were associated with some subtypes of epilepsy.
Patients and methods
The present study was carried out in Tanta University Hospi-
tal, Pediatric Department, Neurology unit, during a 12-month
period from January 2011 to January 2012. Forty children
with refractory epilepsy 25 males and 15 females, age range
4–15 years with the mean age of 9.17 ± 3.4 years were selected
for this study. Patients with refractory epilepsy had recurrent
seizures for more than 18 months with no more than a 3-
month seizure free period during those 18 months and failure
of at least two appropriate AEDs with proper doses, good
compliance and within normal therapeutic range, Table 1.
Thorough history of the age of onset, detailed medical history,
types of seizures, frequency, duration, history of the AEDs
Table 2 Types of seizures in children with refractory epilepsy.
Type Number %
partial seizures 22 55
Generalized tonic clonic seizures 6 15
Myoclonic seizures 4 10
Atonic seizures 6 15
Mixed types of seizures 2 5
Total 40 100
48 S.A. Abd El-Aziz, H. El-Serogygiven including the dose and the compliance and duration as
well as family history of similar conditions, obstetric history
of any complication during delivery and past history of trauma
were obtained from the parents. Electroencephalography
(EEG) and Magnetic Resonance Imaging (MRI) brain, and
the serum level of the AEDs were done for the epileptic chil-
dren. Exclusion criteria included, false refractoriness related
to non-epileptic seizures, inadequate AEDs, poor combination
of AEDs, sub therapeutic range of AEDs, non-compliance and
seizure-precipitating factors. Also children with chronic
inﬂammatory diseases, diabetes mellitus, liver or renal impair-
ment, cardiac and pulmonary diseases were excluded from the
study. Twenty (20) children with controlled idiopathic epilepsy
15 males and 5 females newly diagnosed as suffering from var-
ious types of seizures generalized and partial types were in-
cluded, 16 of them had generalized seizures and 4 children
had partial seizures, aged 4–13 years with the mean age being
10.1 ± 3.1 years. These children were free of any neurological
diseases and had normal brain Magnetic Resonance Imaging
(MRI). They were free of any systemic diseases by clinical
and neurological examination, they had two or more unpro-
voked seizures and abnormal Electroencephalography (EEG)
and diagnosed as idiopathic epilepsy, these children are seizure
free six months ago. These children with idiopathic epilepsy
were included in this study for comparison with children with
refractory epilepsy as regard to the serum ANA and GADA.
Complete blood count including cell count for the major im-
mune cell populations i.e., neutrophils, lymphocytes, eosino-
phils, monocytes and platelets was done. Other routine
laboratory tests, including liver function, kidney function
and fasting blood sugar were done for all children. Serum anti-
nuclear antibodies (ANA) and autoantibodies to glutamic acid
decarboxylase (GADA) were measured for all children. All
children participated in the study after written informed paren-
tal consent was obtained. The local ethics committee of the
Faculty of Medicine Tanta University approves the study.
Venous blood samples were collected in the morning after
an overnight fast. The fasting blood samples were allowed to
clot for 30 min then centrifuged and the serum obtained was
collected into clean dry tubes and stored at 20 C till the time
of the assay for detection of auto antibodies to glutamic acid
decarboxylase (GADA) and antinuclear antibodies(ANA).
Determination of human anti-glutamic acid decarboxylase
(Anti-GAD) by ELIZA kit supplied by Uscn Life Science INC.
Cat. No. E3245Hu
Principle of the assay
The micro titer plate provided in this kit has been pre-coated
with antigen. Standards and samples were then added to the
appropriate micro titer plate wells with a biotin-conjugated
antigen. Next, Avidin conjugated to Horseradish Peroxidase
(HRP) was added to each micro plate well and incubated.
Then a TMB substrate solution was added to each well. Only
those wells that contain Anti-GAD, biotin-conjugated antigen
and enzyme conjugated Avidin exhibited a change in color.
The enzyme–substrate reaction was terminated by the addition
of a sulfuric acid solution and the color change was measured
spectrophotometrically at a wavelength of 450 nm. The con-
centration of Anti-GAD in the samples was then determined
by comparing the O.D. of the samples to the standard curve.20Determination of antinuclear antibody (ANA) by ELIZA kit
supplied by bioassay Cat. No. A2298-12J
Principle of the assay
Anti-nuclear antibodies (ANA) ELISA kit was based on bind-
ing of ANA from standard and serum samples to extracted nu-
clear antigen (ENA) immobilized on micro titer wells. After a
washing step, goat anti-mouse HRP conjugate was added.
After another washing step, to remove all the unbound enzyme
conjugate, chromogenic substrate (TMB) was added and color
developed. The enzymatic reaction (blue color) was directly
proportional to the amount of ANA present in the sample.
The reaction was terminated by adding stopping solution (con-
verts blue to yellow). Absorbance was then measured on a mi-
cro titer well ELISA reader at 450 nm.21
Statistical analysis
Collected data were coded, analyzed and computed using the
Statistical Package for Social Sciences (SPSS) version 10. Re-
sults are expressed as mean ± SD, and differences between
the means of different variables tested using the Student’s t-
test. Differences were considered statistically signiﬁcant when
P< 0.05. Pearson correlation was done to correlate the dura-
tion of refractory epilepsy and the serum ANA and GAD
antibodies.
Results
Table 1 shows the characteristics of children with refractory
epilepsy with regard to the age of the children, currently used
AEDs, duration of treatment, age of the ﬁrst seizure in years
and the EEG ﬁnding in these children. Table 2 shows the
types of seizures in children with refractory epilepsy, 55%
of them had partial seizures, 15% had generalized tonic clo-
nic seizures, 10% had myoclonic seizures, 15% had atonic
seizures and 5% had mixed type of seizures. Table 3 shows
the frequency of seizures in children with refractory epilepsy,
70% of them had the frequency of Ponce/month, 25% of
them had the frequency of Ponce/week, 5% of them had
the frequency of once/day. Table 4 shows the types of AEDs
used, 15% of children with refractory epilepsy treated with
valproic acid + carbamazepine, 30% of these children treated
with valproic acid + levetiracetam, 20% of them treated with
carbamazepine + lamotrigine, 15% treated with valproic
acid + topiramate, 10% treated with valproic acid + leveti-
racetam + carbamazepine, another 10% treated with val-
proic acid + topiramate + clonazepam. Table 5 shows the
serum ANA levels in children with refractory epilepsy and
Table 3 Frequency of seizures in children with refractory
epilepsy.
Frequency Number %
POnce/month 28 70
POnce/week 10 25
Once/day 2 5
Total 40 100
Table 4 Types of antiepileptic drugs (AEDs).
Antiepileptic drugs Number %
Valproic acid + carbamazepine 6 15
Valproic acid + levetiracetam 12 30
Carbamazepine + lamotrigine 8 20
Valproic acid + topiramate 6 15
Valproic acid + levetiracetam+ carbamazepine 4 10
Valproic acid + topiramate + clonazepam 4 10
Table 5 Serum antinuclear antibody in children with refrac-
tory epilepsy and children with controlled epilepsy (U/L).*
ANA (U/L) Refractory epilepsy Controlled epilepsy P Value
Range 15–60 5–30 <0.001
Mean ± SD 36.9 ± 11.3* 16.3 ± 7.2
* Signiﬁcant: P< 0.05.
Table 6 Serum glutamic acid decarboxylase antibody in
children with refractory epilepsy and children with controlled
epilepsy (ng/ml).
GAD antibody
(ng/ml)
Refractory
epilepsy
Controlled
epilepsy
P Value
Range 50–200 10–110
Mean ± SD 111.3 ± 33.7* 65.2 ± 30.22 <0.001
* Signiﬁcant: P< 0.05.
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Figure 1 Correlation between the serum levels of ANA and the
duration of refractory epilepsy. r: 0.975; P< 0.001.
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Figure 2 Correlation between the serum levels of GAD anti-
bodies and the duration of refractory epilepsy. r: 0.99; P< 0.001.
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cantly higher in children with refractory epilepsy than the ser-
um level of ANA in children with controlled epilepsy
P< 0.001. Table 6 shows the serum GAD antibodies in chil-
dren with refractory epilepsy and children with controlled
epilepsy. Serum GAD antibody levels were signiﬁcantly high-
er in children with refractory than in children with controlled
epilepsy P< 0.001. Fig. 1 shows a correlation between the
serum levels of ANA and the duration of refractory epilepsy.
There was a signiﬁcant correlation between the duration of
refractory epilepsy and the serum ANA, r: 0.975,
P< 0.001. Fig. 2 shows a correlation between the serum lev-
els of GAD antibodies and the duration of refractory epi-
lepsy. There was a signiﬁcant correlation between the
duration of refractory epilepsy and the serum GAD antibod-
ies r: 0.99, P< 0.001. Increased duration of refractory epi-
lepsy was associated with increased serum levels of ANA
and GADA.
Discussion
In a substantial number of patients with epilepsy, the etiology
of the seizure disorder remains unknown.22 In recent years, the
detection of autoantibodies has contributed to the etiologic
understanding of a substantial number of unexplained epilep-
sies.23 The concept that the immune system plays a role in the
epileptogenic process of some epileptic syndromes was ﬁrst
proposed more than 20 years ago.24 This study assessed the
prevalence of ANA and GADA in children with refractory
and controlled epilepsies. Increased prevalence of ANA and
GADA has been reported in patients with refractory epi-
lepsy.25 It is highly possible that the production of antineuro-
nal antibodies might be initiated by prolonged seizures leading
to blood–brain barrier leakage, it is still remarkable to observe
a relatively increased incidence of anti-neuronal antibodies in a
group of patients with long-term epilepsy, since these antibod-
ies might still at least partially be participating in epilepsy
pathogenesis and somewhat increasing the seizure severity
and frequency.26 High GADA and ANA titers were present
in patients with refractory epilepsy suggesting that the most
probable origin of their epilepsy is autoimmune and an active
ongoing immunologic process in the brain.27 GADA seem to
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ceptibility.28 Sera from GADA-positive patients with epilepsy
caused a signiﬁcant increase in the frequency of inhibitory
postsynaptic potentials in hippocampal neurons, supporting
that GAD autoimmunity is involved in the pathophysiology
of neuronal dysfunction.29 The synthesis of the inhibitory neu-
rotransmitter GABA was decreased in knockout mice lacking
GAD, leading to spontaneous seizures supporting the impor-
tance of GAD in neuronal excitability.30 A relationship be-
tween epilepsy and GADA and ANA suggesting a possible
role of such antibodies in the pathophysiology of epilepsy,
antiglutamic acid decarboxylase (anti-GAD) antibodies in
the serum and cerebrospinal ﬂuid (CSF) has been reported in
patients with drug-resistant epilepsy, some patients with
drug-resistant epilepsy have evidence of GAD autoimmu-
nity.31 The results of the present study had shown that, chil-
dren with refractory epilepsy had increased serum levels of
ANA and GAD antibodies in comparison to children with
controlled epilepsy. These results agree with the result ob-
tained by Peltola et al.,32 who had reported that, patients with
refractory epilepsy had higher serum levels of GADA than the
controls. Also the results of the present study agree with the
results obtained by Falip et al.,33 who had found elevated ser-
um levels of GAD antibodies and ANA in adult patients with
temporal lobe epilepsy. On the other hand, the results of the
present study are contradictory to the results obtained by
Kwan et al.,34 who had found no signiﬁcant difference in the
absolute titer of GAD autoantibody between adult patients
with controlled and uncontrolled epilepsy. Glutamic acid
decarboxylase (GAD) catalyzes the transformation of gluta-
mate into c-hydroxybutyric acid (GABA), both are major
inhibitory neurotransmitters of the central nervous system.35
The pathophysiological importance of GADA in our patients
is not clear but low levels of GABA in the brain and CSF are
associated with uncontrolled epilepsy, indicating that GABA is
crucial in seizure suppression.36 In conclusion, we identiﬁed a
subgroup of epileptic patients with high-serum ANA and
GADA. The ﬁnding conﬁrmed the association between high
GADA and refractory epilepsy.37 All the patients with high-ti-
ter GADA in the serum suggesting an immunologic origin of
their epilepsy and high GADA and ANA might indicate an ac-
tive ongoing immunologic process in the brain.13 Based on our
ﬁndings, a study on the effectiveness of immunosuppressive
therapy in patients with refractory epilepsy with high GADA
titer is suggested. Further studies for patients with epilepsy
are needed to clarify the signiﬁcance of GADA in the etiology
of epilepsy because these antibodies themselves may be directly
implicated in causing epilepsy.
Conclusion
We identiﬁed children with refractory epilepsy who had high-
titer of GADA and ANA. This ﬁnding conﬁrmed the associa-
tion between high GADA and refractory epilepsy, suggesting
an immunologic origin of refractory epilepsy. The measure-
ment of these antibodies may be useful in evaluating the out-
come of epilepsy. Immunosuppressive drugs may lead to
improvement in children with refractory epilepsy. Further
studies are needed to clarify the signiﬁcance of GADA in the
etiology of refractory epilepsy. Anti GADA should be actively
sought out in pharmacoresistant epilepsy.References
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